Ownership of Digital Reputation Crucial With Growing Compassionate Use Demand as Companies Target Ever Rarer Diseases with No Real Therapeutic Options and Patient Groups - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Cancer Drug News Issue 668" report to their offering.

As companies target ever rarer diseases with no real therapeutic options and patient groups become more empowered, compassionate use programmes will continue to rise. The increase in US compassionate use approvals represents a great opportunity for digitally astute companies, but for those without a firm grip on their digital reputation, the risks are great.

Greater access to experimental drugs in a digital world allows information about brands to be disseminated quickly. In order to ensure that they remain the authority on their products and the masters of their own digital image, companies must ensure high levels of stakeholder engagement though digital platforms, particularly social media. Failure to take ownership could allow negative perceptions to run unmitigated.

Key Topics Covered:

1. Haematological Cancer

  • Amgen's Kyprolis In Combination Now Available In UK To Treat Relapsed MM

2. Lung Cancer

  • European Alimta Threats Will Place Further Pressure On Lilly
  • IDMC Recommends Stopping Alecensa Phase III Trial Early After Positive Outcomes

3. Genito-Urinary Cancer

  • Ferring Initiates Phase IIIb Trial Of Degarelix ADT Therapy In Advanced PCA And CVD
  • Incyte To Discontinue Phase III Study Of Jakafi Plus Capecitabine In MPC

4. Brain Cancer

  • Combination Approach Increases Commercial Scope For Small Oncolytic Immunotherapy Developers
  • Lannett Gains Temozolomide Approval

5. Melanoma/Skin Cancer

  • Enrolment Begins In Melphalan/HDS System Phase III Trial In Hepatic Dominant OM

6. General Developments

  • Adaptimmune's NY-ESO T-Cell Therapy Granted Breakthrough Therapy Designation
  • Tollys Secures Rights To Riboxx' Apoxxim For TLR3-Positive Cancers
  • Epizyme's Tazemetostat Gains Orphan Drug Designation For MRTs

7. Supportive Therapies

  • EMA Accepts Sandoz' Biosimilar Pegfilgrastim Submission
  • Expanded Injectable Approval Will Not Maintain Emend's Market Position

8. Corporate Activity

  • OncoGenex To Reduce Workforce

For more information visit http://www.researchandmarkets.com/research/ldbjcw/cancer_drug_news

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology Drugs